Cerevance is a revolutionary pharmaceutical company using the proprietary NETSseq platform to develop novel symptomatic and disease modifying therapies for CNS disorders

Leveraging a vast and expanding collection of over 16,000 human brain tissue samples, Cerevance is uncovering subtle molecular changes that contribute to disease progression, providing a potentially …

Apr 1, 2025 · Cerevance is focused on advancing cell type-specific therapies for the treatment of neurodegenerative, psychiatric, and central nervous system-controlled metabolic disorders.

Learn how Cerevance is impacting CNS research around the world and find ways to participate their discovery process.

CVN424, Cerevance’s lead therapeutic, is a first-in-class, oral, non-dopaminergic compound acting on a novel target (GPR6), demonstrated significant and clinically meaningful efficacy in a 135-patient …

Cerevance is focused on the development of precision treatments for central nervous system (CNS) disorders, including chronic neurodegenerative conditions such as Alzheimer's disease, Parkinson's …

Cerevance is a private pharmaceutical company whose lead program, CVN424, a first-in-class compound acting on a novel target, recently demonstrated significant and meaningful efficacy in a …

About Cerevance Cerevance is focused on advancing cell type-specific therapies for the treatment of neurodegenerative diseases and obesity.

Cerevance is focused on the development of treatments for central nervous system (CNS) disorders, with a focus on chronic neurodegenerative conditions such as Alzheimer's disease, Parkinson's …

Cerevance is currently conducting a global Phase 3 clinical study (”ARISE”) to evaluate solengepras as an adjunctive treatment in patients with Parkinson’s disease with motor fluctuations